From a biochemical therapeutic viewpoint, Relafen 750 (the active ingredient) represents a fascinating case of how targeted drug action can reduce pain. Its mechanism primarily involves the blocking of cyclooxygenase (prostaglandin-synthesizing enzymes), specifically COX-2, lowering the synthesis

Relafen 750, labeled as naproxol, signifies a specific example of selective biochemical intervention within the realm of inflammatory conditions. From a therapeutic perspective, its mechanism of operation copyrights upon the inhibition of cyclooxygenase (COX) catalysts , particularly COX-2, participa